Navigation Links
CSA Medical Completes $12.6 Million Series A Financing With Additional Venture Investment From Blue Heron Capital
Date:7/12/2011

BALTIMORE, July 12, 2011 /PRNewswire/ -- CSA Medical, Inc., the leading developer of novel Spray Cryotherapy devices that flash freeze and treat diseased tissue inside the body, today announced that it has completed an oversubscribed $12.6 million Series A Preferred Stock financing with the addition of a venture investment from Blue Heron Capital. Proceeds from the financing will be used to address customer demand and support the launch of CSA Medical's new platform technology. The company is also in discussions with additional institutional investors for Series B funding to accelerate the development of new product indications.

"This successful financing underscores the significant value created by our team," said Bill Floyd, CEO and President of CSA Medical. "Our goal is to become a leading global provider of Spray Cryotherapy solutions that treat multiple disease states to improve patient outcomes, simplify treatment and reduce the cost of healthcare. This funding helps set the stage to achieve this goal and commercialize our new platform technology."

CSA Medical's technology uses extreme cold liquid nitrogen (-196 C) to provide targeted treatment of diseased tissue inside the body. The company's current product platform uses an advanced endoscopic tool to treat esophageal disease. The Spray Cryotherapy system is already in use for treating esophageal disease at nearly 80 top-ranked cancer centers and academic teaching hospitals throughout the United States.

"We are impressed with the strength of CSA Medical's management team and the progress the company has made to-date in the GI space," said Tom Benedetti, Partner at Blue Heron Capital.

"We believe that Spray Cryotherapy has far reaching potential and we look forward to supporting the company's efforts in the marketplace."

About CSA Medical

CSA Medical, Inc. develops and manufactures a proprietary therapeutic interventional platform, the Spray Cryotherapy System, comprised of a device, specialty catheters and agent that allows delivery of therapeutic doses of a cryogen to flash freeze and destroy diseased tissue inside the body. The Company is the first to harness the power of extreme cold (-196 C) liquid nitrogen therapeutic energy delivery inside the body. To learn more, please visit www.CSAmedical.com.


'/>"/>
SOURCE CSA Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
Breaking Medicine News(10 mins):